Sandra Dreike, MS, CGC

Cancer Risk Counselor

Sandra Dreike, MS, CGC is a licensed board-certified genetic counselor who specializes in cancer genetics. She received her Master of Science degree is Genetic Counseling from University of California, Irvine and her bachelor’s degree in Biology from California Polytechnic State University, San Luis Obispo. Sandra joined the City of Hope Division of Clinical Cancer Genomics in 2019. She previously practiced as a genetic counselor in Honolulu, HI where she specialized in cancer genetics and general pediatric and adult genetics. Sandra provides genetic counseling and cancer genetic risk assessments at City of Hope. In addition to patient care she assists with the Intensive Course and is involved in research. Sandra is a member of the National Society of Genetic Counselors (NSGC) and Southern California Genetic Counselors (SCGC)..

Jane Churpek, MD

Assistant Professor, Section of Hematology/Oncology and Center for Clinical Cancer Genetics

Dr. Jane Churpek is an Assistant Professor in the Division of Hematology, Oncology, and Palliative Care at The University of Wisconsin-Madison. She is Board Certified in Internal Medicine, Hematology, and Oncology.  In her clinical practice, she cares for adults with low blood counts due to acquired and inherited causes, including clonal hematopoiesis and inherited bone marrow failure syndromes, and performs diagnosis and management of diverse hereditary cancer predisposition syndromes such as familial leukemia, Li Fraumeni syndrome, BAP1 syndrome, etc.  She runs a translational research program aimed at defining the inherited basis of cancer and bone marrow disorders, especially among understudied tumors and blood disorders.  Her goal is to improve diagnosis, early detection, treatment and, ultimately, prevention of morbidity and mortality for patients with these disorders. Dr. Churpek has contributed to the understanding of several novel hereditary blood cancer predisposition syndromes and the role of inherited predisposition in exposure associated cancers such as therapy-related leukemia and mesothelioma.

Thomas Slavin, MD, FACMG, DABMD

Vice President of Medical Affairs for Oncology

Dr. Slavin is Senior VicePresident of Medical Affairs for Oncology at Myriad Genetics. He is aphysician-scientist, triple-board-certified in clinical genetics, moleculardiagnostics and pediatrics.  Most recently, he served as assistantprofessor in the departments of Medical Oncology & Therapeutics Researchand Population Sciences at City of Hope National Medical Center. Dr. Slavingraduated medical school with Alpha-Omega-Alpha-honors from the University ofSouth Florida. He completed his residency programs at Case Western Reserve inCleveland, Ohio; this training included a postdoctoral research year ingenetic epidemiology. He has also completed graduate course work towards aMasters degree in clinical research through the University of SouthernCalifornia. He is an active member of the American Association of CancerResearch, the American Society of Clinical Oncology (ASCO), the AmericanSociety of Human Genetics, the Collaborative Group of the Americas on InheritedColorectal Cancer, and is a fellow of the American College of Medical Geneticsand Genomics. He has served on National Comprehensive Cancer Network (NCCN)committees for both the genetics of and screening for colorectal cancer. He hasserved on three ClinGen expert working group committees for variantclassification of breast, gastrointestinal and ovarian cancer predispositiongenes.  Focused on expanding genetics education for cancer care providers,Dr. Slavin has helped shape both ASCO University as well as City of Hope’shereditary genomics training program. He is a well-published researcher in thefield of medical genetics, including over 60 journal articles, multiple bookchapters, and numerous presentations at national and international medicalmeetings. He has been involved in many national cancer research grants, and wasa 2018 National Institutes of Health (NIH) K08-career development grantawardee. 

Components visible upon registration.